TOP TEN perturbations for 39867_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39867_at
Selected probe(set): 238190_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39867_at (238190_at) across 6674 perturbations tested by GENEVESTIGATOR:
Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):-2.519988Number of Samples:2 / 10
| Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
| Control | normal epidermal Langerhans cell sample |
| Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |
IgA nephropathy study 4 (ecap. prolif. pos.) / IgA nephropathy study 4 (ecap. prolif. neg.)
Relative Expression (log2-ratio):-2.1795835Number of Samples:2 / 4
| Experimental | IgA nephropathy study 4 (ecap. prolif. pos.) |
| Glomeruli tissue samples obtained by laser-capture microdissection from kidney biopsies from SLE patients (systemic lupus erythematosus) suffering from IgA nephropathy. The kidney biopsies were reviewed by four neuropathologists in a blinded manner and scored as positive for glomerular endocapillary proliferation (E1 in the Oxford MEST scoring system). (Warning: Experiment with gender bias). | |
| Control | IgA nephropathy study 4 (ecap. prolif. neg.) |
| Glomeruli tissue samples obtained by laser-capture microdissection from kidney biopsies from SLE patients (systemic lupus erythematosus) suffering from IgA nephropathy. The kidney biopsies were reviewed by four neuropathologists in a blinded manner and scored as negative for glomerular endocapillary proliferation (E0 in the Oxford MEST scoring system). (Warning: Experiment with gender bias). |
ARC study 1 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):1.7495804Number of Samples:2 / 2
| Experimental | ARC study 1 |
| MCF7 cells treated with 2uM ARC (4-amino-6-hydrazino-7-beta-d-ribofuranosyl-7H-pyrrolo-(2, 3-d)-pyrimidine-5-carboxamide, NSC 188491) for 24 hours. ATC code:--- | |
| Control | untreated MCF-7 cell sample |
| MCF-7 cells untreated. |
Langerhans cell histiocytosis study 2 (multisystem) / Langerhans cell histiocytosis study 2 (unifocal)
Relative Expression (log2-ratio):-1.7045994Number of Samples:2 / 8
| Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
| Control | Langerhans cell histiocytosis study 2 (unifocal) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion). |
sangivamycin study 1 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):1.6149311Number of Samples:2 / 2
| Experimental | sangivamycin study 1 |
| MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:--- | |
| Control | untreated MCF-7 cell sample |
| MCF-7 cells untreated. |
glioma study 16 (astrocytoma) / normal brain tissue
Relative Expression (log2-ratio):1.574481Number of Samples:8 / 2
| Experimental | glioma study 16 (astrocytoma) |
| Primary astrocytoma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade III-IV). | |
| Control | normal brain tissue |
| Normal brain tissue sample from healthy donors. |
HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Relative Expression (log2-ratio):1.5443325Number of Samples:3 / 3
| Experimental | HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) |
| Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C. | |
| Control | HIF-1a/HIF-2a depletion study 1 (normoxia; AB81) |
| Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):1.5157032Number of Samples:2 / 2
| Experimental | T-cell activation study 1 |
| CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
| Control | quiescent CD4+ T-cell sample |
| Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):-1.4678154Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample
Relative Expression (log2-ratio):1.4555016Number of Samples:2 / 2
| Experimental | T-cell activation study 3 |
| CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs. | |
| Control | resting CD4 T-lymphocyte (crude fraction) sample |
| Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction. |
Organism: Homo sapiens
Gene: 39867_at
Selected probe(set): 201113_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39867_at (201113_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):3.4605007Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):3.3068686Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):3.2112103Number of Samples:2 / 3
| Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):3.2054749Number of Samples:2 / 4
| Experimental | glioma study 17 (glioblastoma; unsorted) |
| Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):3.153037Number of Samples:2 / 4
| Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
| Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.601758Number of Samples:3 / 3
| Experimental | glioma study 17 (astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
T-cell activation study 4 / normal resting T-cell sample
Relative Expression (log2-ratio):2.5213308Number of Samples:2 / 2
| Experimental | T-cell activation study 4 |
| T-cell samples antiCD3 activated for 30hrs. | |
| Control | normal resting T-cell sample |
| T cells resting for 30h. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.3469276Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.259798Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-2.2012024Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |